drugset
drugset / Trial / NCT05382325

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

NCT05382325 ↗

Phase 1 Active not recruiting 70 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.

Timeline

Start
2022-06-16
Primary completion
2026-07-31
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-1484 Unknown 0.2 mg Subcutaneous
Subject MK-1484 Unknown 10 mg Subcutaneous
Subject MK-1484 Unknown 60 mg Subcutaneous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

No indication recorded.